QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
Log in
NASDAQ:CRVS

Corvus Pharmaceuticals Stock Forecast, Price & News

$3.80
-0.29 (-7.09 %)
(As of 10/28/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.79
Now: $3.80▼
$4.02
50-Day Range
$3.34
MA: $4.06▼
$4.86
52-Week Range
$1.01
Now: $3.80▼
$6.88
Volume412,500 shs
Average Volume967,396 shs
Market Capitalization$106.54 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Read More
Corvus Pharmaceuticals logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.60 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRVS
Previous Symbol
CUSIPN/A
CIK1626971
Webwww.corvuspharma.com
Phone650-900-4520
Employees49

Debt

Debt-to-Equity RatioN/A
Current Ratio5.24
Quick Ratio5.24

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.42 per share
Price / Book1.57

Profitability

EPS (Most Recent Fiscal Year)($1.59)
Net Income$-46,670,000.00
Net MarginsN/A
Return on Equity-69.51%
Return on Assets-58.07%

Miscellaneous

Outstanding Shares28,036,000
Market Cap$106.54 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$3.80
-0.29 (-7.09 %)
(As of 10/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

How has Corvus Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRVS shares have increased by 40.2% and is now trading at $3.80.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Corvus Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Corvus Pharmaceuticals.

When is Corvus Pharmaceuticals' next earnings date?

Corvus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Corvus Pharmaceuticals.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) issued its quarterly earnings data on Thursday, July, 30th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.08.
View Corvus Pharmaceuticals' earnings history.

What price target have analysts set for CRVS?

3 brokerages have issued twelve-month price targets for Corvus Pharmaceuticals' shares. Their forecasts range from $7.00 to $12.00. On average, they expect Corvus Pharmaceuticals' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 136.8% from the stock's current price.
View analysts' price targets for Corvus Pharmaceuticals.

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a decline in short interest during the month of September. As of September 30th, there was short interest totaling 1,370,000 shares, a decline of 14.4% from the September 15th total of 1,600,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the short-interest ratio is presently 1.3 days. Approximately 6.4% of the company's shares are sold short.
View Corvus Pharmaceuticals' Short Interest.

Who are some of Corvus Pharmaceuticals' key competitors?

Some companies that are related to Corvus Pharmaceuticals include G1 Therapeutics (GTHX), Mirum Pharmaceuticals (MIRM), Silence Therapeutics (SLN), Tricida (TCDA), Rigel Pharmaceuticals (RIGL), resTORbio (TORC), Dynavax Technologies (DVAX), Applied Therapeutics (APLT), Crinetics Pharmaceuticals (CRNX), 89bio (ETNB), Marinus Pharmaceuticals (MRNS), Viking Therapeutics (VKTX), Organogenesis (ORGO), Merus (MRUS) and BELLUS Health (BLUSF).
View all competitors.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and BioNano Genomics (BNGO).

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the following people:
  • Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 68)
  • Mr. Leiv Lea, Chief Financial Officer (Age 65)
  • Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 57)
  • Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 52)
  • Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 53)

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Hikari Power Ltd (0.07%). Company insiders that own Corvus Pharmaceuticals stock include Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller.
View institutional ownership trends for Corvus Pharmaceuticals.

Which major investors are selling Corvus Pharmaceuticals stock?

CRVS stock was sold by a variety of institutional investors in the last quarter, including Hikari Power Ltd.
View insider buying and selling activity for Corvus Pharmaceuticals.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $3.80.

How big of a company is Corvus Pharmaceuticals?

Corvus Pharmaceuticals has a market capitalization of $106.54 million. The company earns $-46,670,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Corvus Pharmaceuticals employs 49 workers across the globe.

What is Corvus Pharmaceuticals' official website?

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]

This page was last updated on 10/28/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.